Skip to main content
. Author manuscript; available in PMC: 2024 Jun 7.
Published in final edited form as: Neuron. 2023 Apr 5;111(11):1795–1811.e7. doi: 10.1016/j.neuron.2023.03.014

Figure 2. Oxytocin in the PL-PFC produces anti-nociceptive effects.

Figure 2.

(A) Hargreaves test with OT delivered intracranially (Ic) to the PL-PFC.

(B) Intracranial OT at 0.5 μg and 1 μg increased withdrawal latency, compared with SAL (paired t test; 1 μg OT versus baseline: ****p < 0.0001; 0.5 μg OT versus baseline: **p < 0.01, SAL versus Baseline: p = 0.2255; n = 6 animals).

(C) Experimental timeline.

(D) Schematic of the CPA assay, where no noxious stimulus (no prick, NP) was paired with one chamber, and noxious PP was paired with the other chamber.

(E) Rats after SAL exhibited aversion to the chamber associated with PP (***p < 0.001, two-way ANOVA with repeated measures and Sidak’s multiple comparisons test; n = 6 animals).

(F) Rats after OT exhibited no aversion to PP (p = 0.9998, same test as F, n = 6 animals).

(G) OT decreased aversion to PP in naïve rats (**p < 0.01, paired t test; n = 6 SAL and OT animals). Data are represented as mean ± S.E.M. See also Figure S3.